Ticker brief
CRVS CORVUS PHARMACEUTICALS INC
Consumer, Non-cyclical · Pharmaceuticals
last close
$14.16
1 day
-3.8%
14 days
-4.9%
mkt cap
$1.3B
signals 14d
9
authors 14d
4
crowd 14d
-0.4σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 66% cheap · 1 pctile own 1y | IV/HV 1.13× (as of 2026-08-18) |
| Skew — 25Δ RR 30d | +0.050 97 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +1.27 elevated | 5-session Δ -0.60 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-04-24 (z=3.0) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-27 · now +0.28 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 6 | +0.42 |
| @tenet_research | C | -0.96 | 1 | +0.10 |
| @OzmosiHealth | C | · | 1 | +0.10 |
| @OptionsFlowBoss | C | · | 1 | +0.75 |
Recent signals9of 9 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @OptionsFlowBoss | +0.75 | Says CRVS is getting ready to surge. | -3.8% | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.10 | Corvus announced publication of final Phase 1/1b lymphoma-trial data. | -3.8% | tweet ↗ |
| 2026-08-27 | @tenet_research | +0.10 | Corvus announced publication of final Phase 1/1b soquelitinib T-cell lymphoma data in Blood. | -3.8% | tweet ↗ |
| 2026-08-27 | @semodough | +0.35 | Describes peer-reviewed mechanism data supporting soquelitinib's broader immune and inflammatory disease potential. | -3.8% | tweet ↗ |
| 2026-08-27 | @semodough | +0.10 | Corvus announced publication of final Phase 1/1b soquelitinib lymphoma data in Blood. | -3.8% | tweet ↗ |
| 2026-08-26 | @semodough | +0.65 | Argues an Angel Hong Kong IPO could expose a large hidden NAV uplift for Corvus. | -3.9% | tweet ↗ |
| 2026-08-25 | @semodough | +0.55 | Argues CRVS has multiple ways to unlock hidden value from a new oral mechanism program. | -2.7% | tweet ↗ |
| 2026-08-19 | @semodough | +0.70 | Argues investors underestimate ITK inhibition and the patent foresight protecting soquelitinib. | -8.1% | tweet ↗ |
| 2026-08-16 | @semodough | +0.15 | Cowen sees a large underpenetrated AD market and projects Rezpeg can generate $6B-plus across indications. | -4.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.